贝伐单抗相关性高血压的发生及处理  

Incidence and Management of Hypertension Induced by Bevacizumab

作　　者：杨琳[1] 严芳[1] 沈倩[1] 刘红云[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院,430030

出　　处：《实用癌症杂志》2013年第6期631-633,共3页The Practical Journal of Cancer

基　　金：湖北省自然科学基金资助项目(编号:2011CDB213)

摘　　要：目的观察贝伐单抗相关性高血压的发生,并探讨其处理方法。方法回顾性分析53例应用贝伐单抗联合化疗的恶性肿瘤患者高血压发生情况及治疗方法。结果 53例晚期恶性肿瘤患者应用贝伐单抗联合化疗后,高血压发生中位时间为46天,发生率为18.9%(10/53),其中3～4级发生率为5.7%(3/53),未出现高血压危象,给予降压治疗后血压均可控制。发生高血压者与未发生高血压者临床疗效比较,无统计学差异(P=0.707)。结论高血压为贝伐单抗常见不良反应,以轻中度为主,合理降压治疗后血压可控制,高血压的发生不能预测贝伐单抗的临床疗效。Objective To investigate the incidence and management of hypertension induced by bevacizumab. Methods Blood pressure and corresponding management of 53 patients with advanced malignant tumors treated with bevacizumab and chemotherapy were retrospectively analysed. Results 53 advanced malignant tumor patients were treated with bevacizumab and chemotherapy. The median time from the initiation of bevacizumab to the beginning of hypertension was 46 days. The incidence of treatment-induced hypertension was 18.9% （ 10/53 ）. And 3 out of the 53 patients（5.7% ） were classified as hypertension of grade 3 -4. No serious cardiac events or hypertensive crisis happened. The blood pressure of the 10 patients was in good controll after corresponding treatment. Univariate analysis revealed that there was no statistical difference in clinical outcome stratified with bevacizumab-induced hypertension（P = 0. 707）. Conclusion In advanced malignant tumor patients treated with bevacizumab and chemotherapy,the incidence of treatment-induced hypertension is high. Most of them are mild to moderate, and respond well to proper treatment. The treatment-induced hypertension isnt predictive factor of response to bevacizumab.

关 键 词：高血压 恶性肿瘤 靶向治疗 贝伐单抗 

分 类 号：R730.5[医药卫生—肿瘤]